Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RT-116
- Development stage
- Preclinical
- Lead developer
- RANI Therapeutics
- Modality
- Drug Delivery Systems
- Administration
- Oral
01
Overview
RT-116 is an investigational drug delivery system that combines semaglutide with Rani Therapeutics' RaniPill HC (High Capacity) technology. It is designed to enable oral delivery of semaglutide, a GLP-1 receptor agonist typically administered via subcutaneous injection. Preclinical studies in canines demonstrated that semaglutide delivered orally via the RaniPill capsule resulted in comparable bioavailability (107% relative to subcutaneous administration), pharmacokinetics, and weight loss effects to subcutaneous administration of semaglutide. The technology aims to replace subcutaneous injection with oral dosing, potentially improving patient compliance and experience.
02
Targets
Beyond the preview
Go deeper on RT-116.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RT-116.